MSNP-Based Delivery System Development
Mesoporous silica nanoparticles (MSNPs) are nanoscale particles composed of silica (silicon dioxide) with a highly ordered porous structure. They typically have a spherical shape and can range in size from several nanometers to hundreds of nanometers. At Alfa Cytology, we have established a proprietary MSNs platform to help you develop novel drug delivery system for bladder cancer.
Introduction to MSNP-Based Delivery System
The excellent biocompatibility, high stability, rigid backbone, good pore structure, tunable surface chemistry and controlled release of drugs of mesoporous silica nanoparticles (MSNPs) determine them to be excellent drug carriers. Their unique properties make them attractive candidates for targeted drug delivery, imaging, and therapeutic monitoring in bladder cancer. Therefore, MSNPs have shown great potential in the field of bladder cancer therapy.
Fig 1. Schematic illustrating the critical advances and specific attributes of engineered MSNs. (Kankala R. K. et al. 2020)
Here are some key advantages of MSNs for bladder cancer:
- Preclinical Imaging
- Biocompatibility and Stability
- Targeted Drug Delivery
- Enhanced Drug Loading Capacity
- Controlled Drug Release
- Combination Therapies
Our Services
Alfa Cytology, a leading company in preclinical contract research organization (CRO) services, Alfa Cytology is working on the development of a mesoporous silica nanoparticle (MSNP)-based drug delivery system for bladder cancer. To further enhance the efficacy and specificity of the MSNP-based drug delivery system, we focus on the following areas:
| Development of Targeting MSNP-Based DDS |
Development of Stimulus Responsive MSNP-Based DDS |
| Passive Targeting MSNPs |
Active Targeting MSNPs
- transferrin (Tf)
- Epidermal growth factor (EGF)
- Hyaluronic acid (HA)…
|
- Temperature-triggered MSNPs
- Ultrasound-triggered MSNPs
- Light-triggered MSNPs
- Magnetically-responsive MSNPs
|
- pH-responsive MSNPs
- Redox potential-responsive MSNPs
- Enzyme-responsive MSNPs
|
 |
 |
 |
By integrating these targeting and stimulus-responsive strategies, we can develop a sophisticated MSN-based drug delivery system that offers enhanced specificity, controlled drug release, and improved therapeutic outcomes for bladder cancer.
Our Solutions Will Help You Achieve the Goals.
- Enhanced Targeting of Bladder Cancer Cells
- Controlled and Triggered Drug Release for Bladder Cancer
- Preclinical Therapeutic Monitoring and Imaging
Contact Us
Alfa Cytology is your trusted partner in the development and translation of MSN-based drug delivery systems for bladder cancer treatment. With our expertise in formulation development, evaluation, and regulatory support, we are well-equipped to assist you in harnessing the advantages of MSNs in enhancing therapeutic outcomes. Contact us today to explore the possibilities of this innovative approach in cancer therapy.
Reference
- Vallet-Regí M., Colilla M., and et al. Mesoporous Silica Nanoparticles for Drug Delivery: Current Insights. Molecules. 2018, 23(1): 47.
For research use only. Not intended for any clinical use.
Related Services
